In a report released today, Ami Fadia from Needham maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $210.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ami Fadia has given his Buy rating due to a combination of factors including Jazz Pharmaceuticals’ recent financial performance and strategic developments. The company reported a non-GAAP EPS of $8.13, surpassing expectations primarily because of a one-time tax impact and a slight revenue increase compared to consensus estimates. Additionally, the company’s management has adjusted its 2025 revenue guidance, maintaining the midpoint at $4.225 billion, while also revising SG&A and R&D expenses to align with portfolio priorities.
Another significant factor influencing the Buy rating is the agreement with the FDA to include all approximately 920 patients in the ITT analysis for the PFS and interim OS readout, expected within the quarter. This inclusion is seen as a positive development, enhancing the robustness of the upcoming data readout. Furthermore, the strong performance of Epidiolex and the promising initial sales of Modeyso contribute to a favorable outlook for Jazz Pharmaceuticals, supporting the Buy recommendation.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $205.00 price target.